<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01033760</url>
  </required_header>
  <id_info>
    <org_study_id>2009-014742-28</org_study_id>
    <secondary_id>EudraCT</secondary_id>
    <nct_id>NCT01033760</nct_id>
  </id_info>
  <brief_title>Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)</brief_title>
  <official_title>Optimisation of Primary HIV1 Infection Treatment (ANRS 147 OPTIPRIM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen-Cilag Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to assess the impact of raltegravir, maraviroc, darunavir/r, and
      Truvada® (emtricitabine/tenofovir) vs. darunavir/r and Truvada® on cell-associated HIV-DNA
      levels in patients with primary HIV-1 infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary HIV-1 infection is characterized by a phase of intense replication, with a quick
      dissemination and early changes in the immune system. During primary HIV-1 infection, damages
      to MALT and GALT promotes a chronic cell activation, which participates in a progressive
      decay of immune functions.

      After HAART initiation, the magnitude and rapidity of cell-associated HIV-DNA decrease are
      significantly higher in patients with primary HIV-1 infection than in patients with chronic
      infection (Ngo Giang Huong, AIDS 2004).

      We hypothesize that an early intervention at different levels of viral replication with
      potent and well-tolerated new drugs may have a greater impact on cell-associated HIV-DNA
      levels than conventional triple-drug HAART.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the 24-month impact of maximized vs. conventional HAART- on HIV reservoirs, as assessed by cell-associated HIV-DNA levels, in patients with acute or primary HIV-1 infection</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma HIV-RNA levels and proportion of patients with plasma viral load &lt; 50 copies/ml at M12, M24 and M30</measure>
    <time_frame>30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma HIV-RNA levels and proportion of patients with plasma viral load &lt; 5 copies/ml at M24</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in cell-associated HIV-DNA between baseline and M24</measure>
    <time_frame>24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the CD4 and CD8 between D0 and M24</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of trial treatments</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and type of ARV mutations in virological failures and change in CCR5 tropism</measure>
    <time_frame>24 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>HIV-1 Infections</condition>
  <arm_group>
    <arm_group_label>arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>darunavir, ritonavir, emtricitabine/tenofovir, maraviroc, raltegravir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>darunavir, ritonavir, emtricitabine/tenofovir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>raltegravir; maraviroc; darunavir; ritonavir; tenofovir/emtricitabine</intervention_name>
    <description>raltegravir (Isentress®): 400 mg bid. maraviroc (Celsentri®): 150 mg bid. darunavir (Prezista®): 800 mg QD. ritonavir tablet (Norvir®): 100 mg QD. tenofovir/emtricitabine (Truvada®): one 245/200 mg tablet QD.</description>
    <arm_group_label>arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>darunavir; ritonavir; emtricitabine/tenofovir</intervention_name>
    <description>darunavir (Prezista®): 800 mg QD. ritonavir tablet (Norvir®): 100 mg QD. tenofovir/emtricitabine (Truvada®): one 245/200 mg tablet QD.</description>
    <arm_group_label>arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with acute or primary HIV-1 infection

          -  Acute infection: negative or slightly positive Elisa, with negative or incomplete
             western-blot (0 or 1 antibody) and positive HIV-RNA and/or positive Ag p24.

          -  Primary infection: positive Elisa with incomplete Western-blot (≥ 2 and &lt; 5 antibodies
             with the presence of anti-p24 antibodies associated with an anti-gp160 or an
             anti-gp120 or an anti-gp41antibody) and positive HIV-RNA.

          -  Symptomatic Primary infection or CD4 &lt;500/mm3

          -  written informed consent

          -  ≥ 18 years old

        Exclusion Criteria:

          -  Prior post exposure antiretroviral treatment within six months before enrolment

          -  Pregnancy or breast-feeding

          -  HIV-2 infection

          -  Current malignancy

          -  Prothrombin time &lt; 50%

          -  Creatinine clearance &lt; 60 ml/min

          -  ASAT, ALAT or bilirubin ≥10*N

          -  Platelets &lt; 25000/mm3
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoine CHERET, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tourcoing Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Caroline LASCOUX-COMBE, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Louis Hospital, Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laurence MEYER, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Methodologist, INSERM U1018</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruno HOEN, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Jacques Hospital, CHU Besançon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isabelle RAVAUX, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Conception Hospital, Marseille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christine ROUZIOUX, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virology Investigator, Necker Hospital Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alain VENET, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Immunology Investigator, INSERM U1012 Bicêtre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel OLIVE, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Immunology Investigator, Cancerology Institut Marseille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gianfranco PANCINO, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Immunology Investigator, Pasteur Institut Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brigitte AUTRAN, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Immunology Investiigator, INSERM U543 Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Gustave Dron</name>
      <address>
        <city>Tourcoing</city>
        <zip>59208</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2009</study_first_submitted>
  <study_first_submitted_qc>December 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2009</study_first_posted>
  <last_update_submitted>February 4, 2014</last_update_submitted>
  <last_update_submitted_qc>February 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary HIV-1 infection</keyword>
  <keyword>antiretroviral treatment</keyword>
  <keyword>HIV reservoirs</keyword>
  <keyword>HIV-DNA levels</keyword>
  <keyword>randomized</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Maraviroc</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

